Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Enrolling by invitation1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

enrolling_by_invitation133%
unknown133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
enrolling_by_invitation

Selected Disorders and Sleep Bruxism

NCT03083405
terminatedphase_3

Pharmacovigilance in Gerontopsychiatric Patients

NCT02374567
unknownearly_phase_1

Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction

NCT03065998

Clinical Trials (3)

Showing 3 of 3 trials
NCT03083405

Selected Disorders and Sleep Bruxism

Enrolling By Invitation
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT03065998Early Phase 1

Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3